• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Malignant effusions: diagnostic evaluation and therapeutic strategy.

作者信息

Memon A, Zawadzki Z A

出版信息

Curr Probl Cancer. 1981 Feb;5(8):1-30. doi: 10.1016/s0147-0272(81)80012-8.

DOI:10.1016/s0147-0272(81)80012-8
PMID:6263549
Abstract
摘要

相似文献

1
Malignant effusions: diagnostic evaluation and therapeutic strategy.
Curr Probl Cancer. 1981 Feb;5(8):1-30. doi: 10.1016/s0147-0272(81)80012-8.
2
Malignant effusions.恶性胸腔积液
CA Cancer J Clin. 1991 May-Jun;41(3):166-79. doi: 10.3322/canjclin.41.3.166.
3
Correctable complications of neoplastic disease. 3. Neoplastic effusions.
Conn Med. 1971 Jun;35(6):411-2.
4
Malignant effusions and their management.
Semin Oncol Nurs. 1985 Nov;1(4):259-68. doi: 10.1016/0749-2081(85)90006-3.
5
Diagnosis and treatment of malignant pleural effusions.恶性胸腔积液的诊断与治疗
Cancer Treat Rev. 1987 Jun;14(2):107-18. doi: 10.1016/0305-7372(87)90043-0.
6
The management of malignant effusions from breast cancer.
J Surg Oncol. 1974;6(5):441-9. doi: 10.1002/jso.2930060508.
7
Approach to the management of pleural effusion in malignancy.恶性肿瘤中胸腔积液的管理方法
South Med J. 1978 Feb;71(2):133-6. doi: 10.1097/00007611-197802000-00013.
8
Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases.复发性胸腔积液和心脏压塞可能是与纳武利尤单抗治疗相关的假性进展的表现-两例报告。
J Immunother Cancer. 2016 Nov 15;4:80. doi: 10.1186/s40425-016-0185-2. eCollection 2016.
9
Diagnostic value of carcinoembryonic antigen assay of pleural & peritoneal effusions in malignancy.癌胚抗原检测对恶性肿瘤患者胸腔及腹腔积液的诊断价值
Indian J Med Res. 1989 Feb;90:22-6.
10
Treatment of malignant pleural and pericardial effusions.
Med Lett Drugs Ther. 1981 Jun 26;23(13):59-60.

引用本文的文献

1
Construction and validation of a predictive model of invasive adenocarcinoma in pure ground-glass nodules less than 2 cm in diameter.构建并验证直径小于 2cm 的纯磨玻璃结节中浸润性腺癌的预测模型。
BMC Surg. 2024 Feb 14;24(1):56. doi: 10.1186/s12893-024-02341-2.
2
Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in -mutated lung cancer patients.在控制EGFR突变型肺癌患者恶性胸腔积液复发方面，腔内化疗联合表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）并不优于TKI单药治疗。
J Thorac Dis. 2019 Sep;11(9):3712-3720. doi: 10.21037/jtd.2019.09.36.
3
Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns.
具有不同胸内转移模式的表皮生长因子受体（EGFR）突变型晚期肺腺癌患者的预后
J Cancer. 2019 Jan 29;10(5):1254-1262. doi: 10.7150/jca.28601. eCollection 2019.
4
Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer.重定向至EphA2的嵌合抗原受体修饰T细胞用于非小细胞肺癌的免疫治疗
Transl Oncol. 2018 Feb;11(1):11-17. doi: 10.1016/j.tranon.2017.10.009. Epub 2017 Nov 10.
5
The Exploration of Peptide Biomarkers in Malignant Pleural Effusion of Lung Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.利用基质辅助激光解吸/电离飞行时间质谱技术探索肺癌恶性胸腔积液中的肽类生物标志物
Dis Markers. 2017;2017:3160426. doi: 10.1155/2017/3160426. Epub 2017 Mar 13.
6
EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.表皮生长因子受体（EGFR）L858R突变增强肺腺癌细胞的侵袭能力，并通过激活CXC趋化因子配体12（CXCL12）-CXC趋化因子受体4（CXCR4）通路促进恶性胸腔积液的形成。
Sci Rep. 2015 Sep 4;5:13574. doi: 10.1038/srep13574.
7
Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.贝伐单抗联合化疗治疗非鳞状非小细胞肺癌相关恶性胸腔积液的疗效
Mol Clin Oncol. 2015 Mar;3(2):415-419. doi: 10.3892/mco.2014.457. Epub 2014 Nov 19.
8
Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion.循环细胞外 miR-134、miR-185 和 miR-22 水平在肺腺癌相关恶性胸腔积液中的诊断价值。
Cancer Res Treat. 2014 Apr;46(2):178-85. doi: 10.4143/crt.2014.46.2.178. Epub 2014 Apr 22.
9
Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma.激活的 Stat3 通过上调组织因子促进肺腺癌恶性胸腔积液的产生，从而增强肿瘤转移和血管通透性。
PLoS One. 2013 Sep 27;8(9):e75287. doi: 10.1371/journal.pone.0075287. eCollection 2013.
10
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.血管内皮生长因子在恶性胸腔积液发病机制、诊断和治疗中的作用。
Curr Oncol Rep. 2013 Jun;15(3):207-16. doi: 10.1007/s11912-013-0315-7.